<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               WARNING: SERIOUS ALLERGIC REACTIONS (INCLUDING ANAPHYLAXIS), PROLONGED AND SEVERE CYTOPENIAS, AND RADIATION EXPOSURE<BR>               <BR>                  <BR>                     Serious Allergic Reactions (Including Anaphylaxis): Serious, including fatal, allergic reactions have occurred during or following administration of the BEXXAR therapeutic regimen. Have medications for the treatment of allergic reactions available for immediate use. Permanently discontinue the BEXXAR therapeutic regimen for serious allergic reactions and administer appropriate medical treatment [see Warnings and Precautions (5.1)].<BR>                  <BR>                  <BR>                     Prolonged and Severe Cytopenias: The BEXXAR therapeutic regimen resulted in severe and prolonged thrombocytopenia and neutropenia in more than 70% of the patients in clinical studies. The BEXXAR therapeutic regimen should not be administered to patients with greater than 25% lymphoma marrow involvement, platelet count less than 100,000 cells/mm3 or neutrophil count less than 1,500 cells/mm3<BR>                        [see Warnings and Precautions (5.2), Adverse Reactions (6.1)].<BR>                  <BR>                  <BR>                     Radiation Exposure: The BEXXAR therapeutic regimen may be administered only under the supervision of physicians who are certified under or participating in the BEXXAR therapeutic regimen certification program and who are authorized under the Radioactive Materials License at their clinical site. Follow institutional radiation safety practices and applicable federal guidelines to minimize radiation exposure during handling and after administration of the BEXXAR therapeutic regimen [see Warnings and Precautions (5.3)]. <BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        WARNING: SERIOUS ALLERGIC REACTIONS/ANAPHYLAXIS, PROLONGED AND SEVERE CYTOPENIAS, AND RADIATION EXPOSURE<BR>                        <BR>                           See full prescribing information for complete boxed warning.<BR>                        <BR>                        <BR>                           ●	Serious Allergic Reactions: Immediately interrupt infusion and permanently discontinue the BEXXAR therapeutic regimen for serious allergic reactions (5.1)<BR>                           <BR>                        <BR>                        <BR>                           ●	Prolonged and severe cytopenias occur in most patients. BEXXAR should not be administered to patients with >25% lymphoma marrow involvement, platelet count <100,000 cells/mm3, or neutrophil count <1,500 cells/mm3 <BR>                              (5.2, 6.1)<BR>                           <BR>                        <BR>                        <BR>                           ●	Radiation Exposure: The BEXXAR therapeutic regimen is supplied only to certified healthcare professionals. Follow institutional radiation safety practices and applicable federal guidelines to minimize radiation exposure to household contacts and medical staff. (5.3)<BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>